Advances in oncological treatment of head and neck carcinomas

01/2018

MUDr. Petra Holečková, Ph.D., MBA¹; as. RNDr. Ing. Libor Staněk, PCTM^2,3,4

1) Ústav radiační onkologie Nemocnice Na Bulovce a 1. LF UK, Praha

2) Onkologická klinika 1. LF UK, Praha

3) Ústav patologie FN Královské Vinohrady, Praha

4) Chirurgická klinika 3. LF UK, Praha

SUMMARY

Carcinoma of the head and neck is a one of cause of cancer-associated illness and death. Most patients present with locoregionally advanced disease, and more than 50% have recurrence within 3 years. Standard of curative care are surgery and radiotherapy. Patients with head and neck carcinoma who progressed or have metastatic disease are treated with platinum-based chemotherapy in combination event. with cetuximab. New treatments agents are checkpoint inhibitors pembrolizumab and nivolumab. Important role in diagnostics and therapy can play molecular biology and genetics.

KEY WORDS

head and neck carcinomas, HPV, EGFR, cetuximab, checkpoint inhibitors, pembrolizumab, nivolumab, molecular biology